| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |




From the Departments of Pathology and Laboratory
Medicine,*
Radiology,
and
Pharmacology,
the Center for
Neurodegenerative Disease Research, University of Pennsylvania,
Philadelphia, Pennsylvania; the University of
Toronto,
Toronto, Ontario, Canada; and the
Department of Pathology,¶
University of
Sherbrooke, Sherbrooke, Quebec, Canada
A novel Congo red-derived fluorescent probe (trans, trans),-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB) that binds to amyloid plaques of postmortem Alzheimers disease brains and in transgenic mouse brains in vivo was designed as a prototype imaging agent for Alzheimers disease. In the current study, we used BSB to probe postmortem tissues from patients with various neurodegenerative diseases with diagnostic lesions characterized by fibrillar intra- or extracellular lesions and compared these results with standard histochemical dyes such as thioflavin S and immunohistochemical stains specific for the same lesions. These data show that BSB binds not only to extracellular amyloid ß protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins and suggests that radioiodinated BSB derivatives or related ligands may be useful imaging agents to monitor diverse amyloids in vivo.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |